Depomed To Present at Three Upcoming Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will provide corporate presentations at the following upcoming investor conferences:

• BIO Investor Forum, Oct. 31 at 8:30 a.m. PT
• Oppenheimer Annual Healthcare Conference, Nov. 4 at 8:00 a.m. ET
• Rodman & Renshaw Annual Healthcare Conference, Nov. 12 at 10:45 a.m. ET

The company will be webcasting its presentations and interested parties can access the live or archived webcasts on the company's website at www.depomedinc.com.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm^TM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA^® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin^® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 (formerly referred to as Gabapentin GR^®) is in clinical development for the treatment of neuropathic pain, and product candidate DM-5689 (formerly referred to as Gabapentin GR^®) is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, www.depomedinc.com.